Literature DB >> 23644663

CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity.

C Zucchini1, M C Manara2, R S Pinca2, P De Sanctis1, C Guerzoni3, M Sciandra4, P-L Lollini1, G Cenacchi5, P Picci6, L Valvassori1, K Scotlandi7.   

Abstract

CD99, a transmembrane protein encoded by MIC2 gene is involved in multiple cellular events including cell adhesion and migration, apoptosis, cell differentiation and regulation of protein trafficking either in physiological or pathological conditions. In osteosarcoma, CD99 is expressed at low levels and functions as a tumour suppressor. The full-length protein (CD99wt) and the short-form harbouring a deletion in the intracytoplasmic domain (CD99sh) have been associated with distinct functional outcomes with respect to tumour malignancy. In this study, we especially evaluated modulation of cell-cell contacts, reorganisation of the actin cytoskeleton and modulation of signalling pathways by comparing osteosarcoma cells characterised by different metastasis capabilities and CD99 expression, to identify molecular mechanisms responsible for metastasis. Our data indicate that forced expression of CD99wt induces recruitment of N-cadherin and β-catenin to adherens junctions. In addition, transfection of CD99wt inhibits the expression of several molecules crucial to the remodelling of the actin cytoskeleton, such as ACTR2, ARPC1A, Rho-associated, coiled-coil containing protein kinase 2 (ROCK2) as well as ezrin, an ezrin/radixin/moesin family member that has been clearly associated with tumour progression and metastatic spread in osteosarcoma. Functional studies point to ROCK2 as a crucial intracellular mediator regulating osteosarcoma migration. By maintaining c-Src in an inactive conformation, CD99wt inhibits ROCK2 signalling and this leads to ezrin decrease at cell membrane while N-cadherin and β-catenin translocate to the plasma membrane and function as main molecular bridges for actin cytoskeleton. Taken together, we propose that the re-expression of CD99wt, which is generally present in osteoblasts but lost in osteosarcoma, through inhibition of c-Src and ROCK2 activity, manages to increase contact strength and reactivate stop-migration signals that counteract the otherwise dominant promigratory action of ezrin in osteosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23644663     DOI: 10.1038/onc.2013.152

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

1.  Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system.

Authors:  Yong Feng; Slim Sassi; Jacson K Shen; Xiaoqian Yang; Yan Gao; Eiji Osaka; Jianming Zhang; Shuhua Yang; Cao Yang; Henry J Mankin; Francis J Hornicek; Zhenfeng Duan
Journal:  J Orthop Res       Date:  2014-10-27       Impact factor: 3.494

2.  CD99-Derived Agonist Ligands Inhibit Fibronectin-Induced Activation of β1 Integrin through the Protein Kinase A/SHP2/Extracellular Signal-Regulated Kinase/PTPN12/Focal Adhesion Kinase Signaling Pathway.

Authors:  Kyoung-Jin Lee; Yuri Kim; Yeon Ho Yoo; Min-Seo Kim; Sun-Hee Lee; Chang-Gyum Kim; Kyeonghan Park; Dooil Jeoung; Hansoo Lee; In Young Ko; Jang-Hee Hahn
Journal:  Mol Cell Biol       Date:  2017-06-29       Impact factor: 4.272

3.  Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99.

Authors:  Haydar Çelik; Marika Sciandra; Bess Flashner; Elif Gelmez; Neslihan Kayraklıoğlu; David V Allegakoen; Jeff R Petro; Erin J Conn; Sarah Hour; Jenny Han; Lalehan Oktay; Purushottam B Tiwari; Mutlu Hayran; Brent T Harris; Maria Cristina Manara; Jeffrey A Toretsky; Katia Scotlandi; Aykut Üren
Journal:  Oncogene       Date:  2018-01-31       Impact factor: 9.867

4.  SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization.

Authors:  B K A Seong; J Lau; T Adderley; L Kee; D Chaukos; M Pienkowska; D Malkin; P Thorner; M S Irwin
Journal:  Oncogene       Date:  2014-09-15       Impact factor: 9.867

5.  The prognostic significance of Src and p-Src expression in patients with osteosarcoma.

Authors:  Chao Hu; Zhouming Deng; Yi Zhang; Lei Yan; Lin Cai; Jun Lei; Yuanlong Xie
Journal:  Med Sci Monit       Date:  2015-02-28

6.  Downregulation of CD99 and upregulation of human leukocyte antigen class II promote tumor aggravation and poor survival in patients with osteosarcomas.

Authors:  Quan Zhou; Jin Xu; Jiali Zhao; Shaoxian Zhang; Wei Pan
Journal:  Onco Targets Ther       Date:  2014-03-24       Impact factor: 4.147

7.  CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2.

Authors:  Marika Sciandra; Maria Teresa Marino; Maria Cristina Manara; Clara Guerzoni; Maria Grano; Angela Oranger; Enrico Lucarelli; Pier-Luigi Lollini; Barbara Dozza; Loredana Pratelli; Maria Flavia Di Renzo; Mario Paolo Colombo; Piero Picci; Katia Scotlandi
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

8.  Facial cutaneo-mucosal venous malformations can develop independently of mutation of TEK gene but may be associated with excessive expression of Src and p-Src.

Authors:  Nabila Brahami; Selvakumar Subramaniam; Moudjahed Saleh Al-Ddafari; Cecile Elkaim; Pierre-Olivier Harmand; Badr-Eddine Sari; Gérard Lefranc; Mourad Aribi
Journal:  J Negat Results Biomed       Date:  2017-03-20

9.  Targeting ROCK2 rather than ROCK1 inhibits Ewing sarcoma malignancy.

Authors:  Rosa Simona Pinca; Maria Cristina Manara; Valentina Chiadini; Piero Picci; Cinzia Zucchini; Katia Scotlandi
Journal:  Oncol Rep       Date:  2017-01-20       Impact factor: 3.906

10.  MicroRNA-144 suppresses osteosarcoma growth and metastasis by targeting ROCK1 and ROCK2.

Authors:  Wei Wang; Xin Zhou; Min Wei
Journal:  Oncotarget       Date:  2015-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.